US Stock MarketDetailed Quotes

ALEC Alector

Watchlist
  • 1.860
  • +0.080+4.49%
Close Dec 20 16:00 ET
  • 1.900
  • +0.040+2.15%
Post 19:58 ET
182.15MMarket Cap-1.09P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Nov 25 15:06
    NEWS
    $Alector (ALEC.US)$
    Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
    Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefit...
    Jaguar8
    Jaguar8
    Sep 19 07:24
    NEWS
    $Alector (ALEC.US)$
    Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
    Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GR...
    Jaguar8
    Jaguar8
    Jul 28 07:06
    NEWS
    $Alector (ALEC.US)$
    Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
    Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
    The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
    Key point...
Read more
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
MicroStrategy
MSTR
+11.56%
Adobe
ADBE
+2.24%
Salesforce
CRM
+2.21%
Apple
AAPL
+1.88%
Meritage Homes
MTH
+1.78%

Unlock the Full List